Makair Oral Suspension is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg per 5 ml, formulated for the management of allergic conditions. Levocetirizine, a selective second-generation antihistamine, acts by inhibiting peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, which play a key role in the pathophysiology of asthma and allergic rhinitis by mediating bronchoconstriction, mucus secretion, and inflammation. The combination of these agents provides a dual mechanism of action, offering enhanced symptomatic relief in patients with allergic rhinitis, asthma, and other hypersensitivity reactions. Makair Oral Suspension is indicated for pediatric and adult patients requiring convenient dosing and improved compliance. It is generally well tolerated; however, potential side effects include headache, somnolence, gastrointestinal disturbances, and rare neuropsychiatric events. Caution is advised in patients with hepatic or renal impairment. Makair Oral Suspension should be administered as directed by a healthcare professional, and it is contraindicated in individuals with known hypersensitivity to either component. This formulation facilitates ease of administration in patients with difficulty swallowing tablets, ensuring effective allergy management.